CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI

Trial Profile

CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Candesartan cilexetil (Primary) ; Lisinopril
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Acronyms CALIBREX
  • Most Recent Events

    • 03 Oct 2017 Planned End Date changed from 1 Dec 2017 to 15 Nov 2018.
    • 03 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 15 Nov 2018.
    • 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top